

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

ORIGINAL INVESTIGATIONS

Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19

Girish N. Nadkarni, MD, MPH, CPH, ^{a,b,c,d,*} Anuradha Lala, MD, ^{a,e,f,*} Emilia Bagiella, PHD, ^{e,f,g} Helena L. Chang, PHD, ^{e,h} Pedro R. Moreno, MD, ^f Elisabet Pujadas, MD, PHD, ^g Varun Arvind, BS, ^{h,i} Sonali Bose, MD, MS, ^b Alexander W. Charney, MD, PHD, ^{a,j,k} Martin D. Chen, MD, ^l Carlos Cordon-Cardo, MD, PHD, ^g Andrew S. Dunn, MD, ^b Michael E. Farkouh, MD, ^m Benjamin S. Glicksberg, PHD, ^{a,c,k} Arash Kia, MD, ^e Roopa Kohli-Seth, MD, ⁿ Matthew A. Levin, MD, ^{a,l} Prem Timsina, PHD, ^e Shan Zhao, MD, PHD, ^l Zahi A. Fayad, PHD, ^{a,f,o,p} Valentin Fuster, MD, PHD^{f,q,*}

ABSTRACT

BACKGROUND Thromboembolic disease is common in coronavirus disease-2019 (COVID-19). There is limited evidence on the association of in-hospital anticoagulation (AC) with outcomes and postmortem findings.

OBJECTIVES The purpose of this study was to examine association of AC with in-hospital outcomes and describe thromboembolic findings on autopsies.

METHODS This retrospective analysis examined the association of AC with mortality, intubation, and major bleeding. Subanalyses were also conducted on the association of therapeutic versus prophylactic AC initiated \leq 48 h from admission. Thromboembolic disease was contextualized by premortem AC among consecutive autopsies.

RESULTS Among 4,389 patients, median age was 65 years with 44% women. Compared with no AC (n = 1,530; 34.9%), therapeutic AC (n = 900; 20.5%) and prophylactic AC (n = 1,959; 44.6%) were associated with lower in-hospital mortality (adjusted hazard ratio [aHR]: 0.53; 95% confidence interval [CI]: 0.45 to 0.62 and aHR: 0.50; 95% CI: 0.45 to 0.57, respectively), and intubation (aHR: 0.69; 95% CI: 0.51 to 0.94 and aHR: 0.72; 95% CI: 0.58 to 0.89, respectively). When initiated \leq 48 h from admission, there was no statistically significant difference between therapeutic (n = 766) versus prophylactic AC (n = 1,860) (aHR: 0.86; 95% CI: 0.73 to 1.02; p = 0.08). Overall, 89 patients (2%) had major bleeding adjudicated by clinician review, with 27 of 900 (3.0%) on therapeutic, 33 of 1,959 (1.7%) on prophylactic, and 29 of 1,530 (1.9%) on no AC. Of 26 autopsies, 11 (42%) had thromboembolic disease not clinically suspected and 3 of 11 (27%) were on therapeutic AC.

CONCLUSIONS AC was associated with lower mortality and intubation among hospitalized COVID-19 patients. Compared with prophylactic AC, therapeutic AC was associated with lower mortality, although not statistically significant. Autopsies revealed frequent thromboembolic disease. These data may inform trials to determine optimal AC regimens. (J Am Coll Cardiol 2020;76:1815-26) © 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation.



Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.

From the ^aMount Sinai Covid Informatics Center, New York, New York; ^bDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; ^cThe Hasso Plattner Institute of Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York; ^dThe Charles Bronfman Institute of Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; ^eDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York; ^fThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York; ^gDepartment of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York; ^hThe Center for Biostatistics at the Icahn School of Medicine at Mount Sinai, New York; New York; ^hThe Center for Biostatistics at Mount Sinai, New York, New York; ^jDepartment of Population Sinai, New York, New York; Icahn School of Medicine at Mount Sinai, New York; ^hThe Center for Biostatistics at the Icahn School of Medicine at Mount Sinai, New York, New York; ^lDepartment of Population Sinai, New York, New York; ^lDepartment of Population School of Medicine at Mount Sinai, New York; ^lDepartment of Population School of Medicine at Mount Sinai, New York; ^lDepartment of Population School of Medicine at Mount Sinai, New York; ^lDepartment of Population School of Medicine at Mount Sinai, New York, New York; ^lDepartment of Population School of Medicine at Mount Sinai, New York, ^lDepartment of Population School of Medicine at Mount Sinai, New York, ^lDepartment of Population School of Medicine at Mount Sinai, New York, ^lDepartment of Population School of Medicine at Mount Sinai, New York, ^lDepartment of Population School of Medicine at Mount Sinai, New York, ^lDepartment of Population School of Medicine at Mount Sinai, New York, ^lDepartment of Population School of Medicine at Mount Sinai, New York, New York; ^lDepartment of Population School of Medicine

ABBREVIATIONS AND ACRONYMS

AC = anticoagulation

CI = confidence interval COVID-19 = coronavirus

disease-2019

DOAC = direct oral anticoagulant

HR = hazard ratio

IPTW = inverse probability treatment weighted

LMWH = low molecular weight heparin

PRBC = packed red blood cell UFH = unfractionated heparin oronavirus disease-2019 (COVID-19) has led to >22 million affected (1) and >784,000 deaths worldwide. Among hospitalized patients, new thromboembolism has emerged as an important disease manifestation (2-5). Autopsy studies have corroborated these observations by demonstrating a high incidence of macrothrombi and microthrombi (6-8). Accordingly, it has been hypothesized that inflammation associated with SARS-CoV-2 infection leads to a "COVID-19-related coagulopathy" (5), resulting in increased thrombosis (6).

Observational analyses have suggested potential benefit for in-hospital use of anticoagulation (AC) in COVID-19 treatment (9,10).

SEE PAGE 1827

Yet, practice patterns vary significantly due to lack of rigorous evidence for optimal regimens. Specifically, anticoagulant choice, dosing, and treatment duration are not well understood. In a preliminary analysis of 2,700 patients admitted to the Mount Sinai Health System in New York, we found an association between in-hospital therapeutic AC and lower mortality compared with patients on no/prophylactic AC (9). The present analysis expands upon those results in a larger cohort to explore the impact of therapeutic and prophylactic AC, as well as choice of agent, on survival, intubation, and major bleeding compared with no AC. We also review the first consecutive autopsies performed at our institution and describe their pre-mortem management as related to AC.

METHODS

DATA SOURCES. Data were retrieved from the electronic health record. Variables collected included demographics, laboratory measurements, vital signs, disease diagnoses, comorbidities, procedures, and outcomes (death, intubation, and hospital discharge). The Mount Sinai Institutional Review Board approved this study.

STUDY DESIGN AND PARTICIPANTS. We included all patients age >18 years admitted with laboratory-confirmed SARS-CoV-2 infection between March 1, 2020, and April 30, 2020, to 5 New York City hospitals. Patients who left the hospital within 24 h of admission as well as those patients treated with both therapeutic and prophylactic regimens of AC during their hospitalization were excluded. If treated for <48 h total with a therapeutic or prophylactic dose, they were conservatively categorized as "not treated with AC" unless AC was stopped due to major bleeding (Supplemental Figure 1). Details on how patients were categorized into therapeutic/prophylactic AC are in the Supplemental Appendix.

EXPOSURES. The primary exposure of interest was therapeutic or prophylactic AC compared with no AC. We also conducted a subanalysis of patients initiated therapeutic or prophylactic anticoagulants within 48 h of admission.

OUTCOMES. The primary endpoint was in-hospital mortality. Secondary endpoints were intubation and major bleeding. Consistency checks were performed to properly align these data tables and minimize missing data. If the amount of missing data was <1%, the

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the *JACC* author instructions page.

Manuscript received August 3, 2020; revised manuscript received August 20, 2020, accepted August 20, 2020.

at Mount Sinai, New York, New York; ^kDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York; ¹Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; "Peter Munk Cardiac Centre and the Heart and Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Ontario, Canada; "Institute for Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; 'BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; ^pDepartment of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York; and the ^qCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. *Drs. Nadkarni, Lala, and Fuster contributed equally to this work. This study is funded by U54 TR001433-05 from the National Institutes of Health. The funding source had no role in the writing of the manuscript or the decision to submit it for publication. Dr. Nadkarni has received grants, personal fees, and nonfinancial support from Renalytix AI; has received nonfinancial support from Pensieve Health; and has received personal fees from AstraZeneca, BioVie, and GLG Consulting outside of the submitted work. Dr. Lala has received personal fees from Zoll outside of the submitted work. Dr. Dunn has received grants from Pfizer: and has received personal fees from Bristol Myers Squibb outside of the submitted work. Dr. Farkouh has received grants from Amgen, Novo Nordisk, and Novartis outside of the submitted work. Dr. Fayad has received grants from Daiichi-Sankyo, Amgen, Bristol Myers Squibb, and Siemens Healthineers; has received personal fees from Alexion, GlaxoSmithKline, and Trained Therapeutix Discovery outside of the submitted work; and has patents licensed to Trained Therapeutix Discovery. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Deepak L. Bhatt, MD, MPH, served as Guest Editor-in-Chief for this paper.

patient was considered as not having the condition (e.g., for comorbidities). Missing values were mostly present for the vitals and the laboratory data, for which we used a "missing" category in the propensity score models to account for the missing data (Supplemental Appendix). Major bleeding was using International Classification defined of Diseases-10th Revision codes (Supplemental Table 1) or receiving ≥ 2 packed red blood cell (PRBC) transfusions within 48 h. Two physicians (G.N.N. and S.Z.) reviewed bleeding cases (n = 153) to adjudicate major bleeding. Disagreements were resolved by consensus discussion with an independent physician (V.F.). Criteria for confirmation of major bleeding included: 1) physician documentation of an active source of bleeding; 2) confirmatory imaging or other evidence (neuroimaging for intracranial bleed); 3) bleeding necessitating \geq 2 PRBC transfusion within 48 h; or 4) suspected bleeding without confirmation of an active bleeding source. PRBCs transfused for other reasons included: 1) chronic anemia (dialysis or other reasons like cancer); 2) maintenance of hemoglobin over 7 g/dl; and 3) other reasons (perioperative or symptom improvement). We also ascertained the bleeding site.

AUTOPSY DATA. Autopsies were performed at the Mount Sinai Hospital after obtaining appropriate consent and verifying SARS-CoV-2 infection status by nasopharyngeal swab unless already appropriately documented. Examinations were carried out in a negative pressure room with enhanced airborne precautions. Histological processing of tissue blocks was performed in standard fashion after extended formalin-fixation. Slides were reviewed by a team of pathology subspecialists.

STATISTICAL ANALYSIS. General characteristics of the sample were summarized using appropriate descriptive statistics for continuous and categorical variables. Some continuous variables (e.g., body mass index, age, D-dimer, respiratory rate, and oxygen saturation) were categorized using clinically meaningful cutpoints to improve interpretability. Patients were divided into 3 groups according to whether they were treated with a therapeutic regimen, prophylactic regimen, or no anticoagulant. Patients receiving both therapeutic and prophylactic anticoagulants were excluded.

Inverse probability treatment weighted (IPTW) models, were used to correct for the potential bias brought about by AC indication. A multinomial logistic model was fit with therapeutic, prophylactic, or no use of AC during the hospitalization as the dependent variable, and age, sex, race and ethnicity, body mass index, history of hypertension, atrial

fibrillation, heart failure, chronic kidney disease or renal failure, use of anticoagulants or antiplatelet agents prior to hospitalization, month of admission, intubation during hospitalization, time of implementation of institutional guidelines for AC at Mount Sinai, respiratory rate, oxygen saturation, and D-dimer at admission as the predictors. These predictors were chosen based on clinical judgment and model fit. We derived stabilized inverse IPTW by multiplying the inverse of the predicted probability of treatment from the propensity score model by the observed probability of treatment. The IPTW approach was used in all analyses. A robust variance was estimated in all models to account for the clustering effect resulting from IPTW. Standardized differences were calculated to determine the level of adjustment induced by the IPTW. To account for residual confounding, all models were adjusted for variables with absolute standardized differences >0.2 (Supplemental Figure 1). Regarding missing data, if the amount of missingness was <1%, a patient was considered as not having the condition (e.g., for comorbidities). Missing values were mostly in vitals and laboratory data (e.g., D-dimer), for which we used a "missing" category in the propensity score models to account for the missing data.

The primary analysis used IPTW Fine and Gray's subdistribution hazard models to determine AC association with in-hospital mortality (11). Survival in days was calculated as time from hospital admission to inhospital death, discharge, or the date of dataset lock (May 7, 2020). Patients who were still hospitalized at the time of the data lock were censored. Discharge alive was considered a competing risk. To minimize immortal time bias, therapeutic and prophylactic AC use were entered in the model as time-dependent variables and similarly for intubation status. The multivariable model also accounted for admission respiratory rate and oxygen saturation.

For the time to intubation analysis, the time between hospital admission and intubation was considered in IPTW competing risk models using the method of Fine and Gray. Death and hospital discharge were considered competing events, and patients who were in hospital but not intubated at the time of data lock were censored. AC use was entered as time-dependent variables with the same covariate adjustment made previously. The hazard ratios (HRs) and their respective 95% confidence intervals (CIs) are reported for all time-to-event models. Frequency tables were used to describe the association between AC use and bleeding events. A similar approach was used for the subgroup of patients treated with therapeutic or prophylactic anticoagulants within 48 h of admission.

TABLE 1 Baseline Characteristics of Patients Stratified by Therapeutic, Prophylactic, and No Anticoagulation (n = 4,389)

	n	Total (N = 4,389)	Therapeutic Anticoagulation (n = 900)	Prophylactic Anticoagulation (n = 1,959)	No Anticoagulation $(n = 1,530)$	p Value*
Age, yrs	4,389	65 (53-77)	70 (59-80)	65 (54-76)	61 (45-75)	< 0.001
Female	4,389	1,932 (44.0)	353 (39.2)	851 (43.4)	728 (47.6)	<0.001
Race/ethnicity	4,389				- 、 - /	0.01
Black		1,152 (26.2)	228 (25.3)	567 (28.9)	357 (23.3)	
Hispanic		1,172 (26.7)	222 (24.7)	523 (26.7)	427 (27.9)	
White		1,060 (24.2)	234 (26.0)	432 (22.1)	394 (25.8)	
Asian		201 (4.6)	38 (4.2)	94 (4.8)	69 (4.5)	
Other		804 (18.3)	178 (19.8)	343 (17.5)	283 (18.5)	
Body mass index, kg/m ²	3,940	28 (25-33)	29 (25-34)	28 (24-32)	28 (24-33)	<0.001
Current smoking	3,405	184 (5.4)	29/687 (4.2)	92/1,533 (6.0)	63/1,185 (5.3)	0.23
Comorbid conditions	-,					
Asthma	4,377	274 (6.3)	59/896 (6.6)	137/1,958 (7.0)	78/1,523 (5.1)	0.07
Chronic obstructive pulmonary disease	4,377	216 (4.9)	61/896 (6.8)	102/1,958 (5.2)	53/1,523 (3.5)	<0.001
Type 2 diabetes	4,377	991 (22.6)	243/896 (27.1)	462/1,958 (23.6)	286/1,523 (18.8)	< 0.001
Hypertension	4,380	1,526 (34.8)	362/898 (40.3)	706/1,959 (36.0)	458/1,523 (30.1)	<0.001
Coronary artery disease	4,352	541 (12.4)	152/895 (17.0)	224/1,950 (11.5)	165/1,507 (10.9)	< 0.001
Atrial fibrillation	4,352	298 (6.8)	158/895 (17.7)	49/1,950 (2.5)	91/1,507 (6.0)	< 0.001
Heart failure	4,380	362 (8.3)	104/898 (11.6)	139/1,959 (7.1)	119/1,523 (7.8)	< 0.001
Chronic kidney disease	4,352	493 (11.3)	105/895 (11.7)	239/1,950 (12.3)	149/1,507 (9.9)	0.08
End-stage kidney disease	4,286	291 (6.8)	56/835 (6.7)	144/1,938 (7.4)	91/1,513 (6.0)	0.26
Liver disease	4,286	69 (1.6)	9/835 (0.7)	38/1,938 (2.0)	22/1,513 (1.5)	0.20
						0.14
Cancer	4,377	340 (7.8)	78/896 (8.7)	160/1,958 (8.2) 39/1,958 (2.0)	102/1,523 (6.7)	
HIV/AIDS	4,377	73 (1.7)	9/896 (1.0)	39/1,938 (2.0)	25/1,523 (1.6)	0.56
Medications at baseline	4 290	221 (7 5)	60 (77)	124 (6.9)	170 (0 4)	0.24
ACE inhibitor or ARB	4,389	331 (7.5)	69 (7.7)	134 (6.8)	128 (8.4)	0.24
Anticoagulant	4,389	79 (1.8)	43 (4.8)	7 (0.36)	29 (1.9)	< 0.001
Antiplatelet agents	4,389	374 (8.5)	69 (7.7)	174 (8.9)	131 (8.6)	<0.001
Initial vital signs	4 2 4 7	120 (125 155)	142 (120, 150)	140 (125 156)	126 (122 151)	0.001
Systolic blood pressure, mm Hg	4,347	138 (125-155)	143 (128-158)	140 (125-156)	136 (122-151)	< 0.001
Diastolic blood pressure, mm Hg	4,347	80 (72-89)	83 (75-91)	80 (72-89)	79 (72-87.5)	< 0.001
Heart rate, beats/min	4,354	99 (88-113)	102 (89-119)	99 (88-112)	98 (87-111)	< 0.001
Oxygen saturation, %	4,275	94 (90-96)	92 (88-95)	94 (91-96)	95 (92-97)	< 0.001
Respiration, breaths/min	4,354	20 (18-24)	22 (20-30)	20 (18-24)	20 (18-20)	<0.001
Initial laboratory tests						
Hemoglobin, g/dl	3,557	12.7 (11.2-14.0)	12.6 (11.0-13.9)	12.8 (11.4-14.1)	12.6 (11.0-13.9)	< 0.001
White blood cell count, cells/mm ³	4,206	7.6 (5.5-10.6)	8.5 (6.0-11.9)	7.3 (5.3-10.0)	7.5 (5.6-10.5)	<0.001
Lymphocyte, %	3,831	9.8 (6.0-15.5)	8.2 (5.2-13.0)	9.8 (6.1-15.2)	11.0 (6.6-17.8)	< 0.001
Neutrophil, %	3,831	66 (44.2-80.7)	75.6 (47.5-85.1)	56.9 (42.6-78.9)	67 (44.9-79.8)	<0.001
D-dimer, µg/ml	3,259	1.7 (0.9-3.6)	2.3 (1.2-5.8)	1.5 (0.8-2.9)	1.7 (0.8-3.7)	<0.001
Ferritin, ng/ml	3,389	706 (317-1,617)	830 (417-1,969)	710 (316-1,594)	601 (272-1,437)	<0.001
Lactate dehydrogenase, U/l	3,268	414 (311-564)	484 (366-670.5)	402 (310-534)	380 (279-512)	<0.001
C-reactive protein, mg/l	3,524	108 (51-195)	141 (65-234)	106 (54-186)	90 (34-168)	<0.001
Procalcitonin, ng/ml	3,124	0.2 (0.1-0.6)	0.2 (0.1-0.7)	0.2 (0.1-0.6)	0.1 (0.1-0.6)	<0.001
Albumin, g/dl	4,033	3.1 (2.8-3.5)	3.0 (2.7-3.4)	3.2 (2.8-3.6)	3.1 (2.7-3.6)	<0.001
Total bilirubin, mg/dl	2,240	0.6 (0.4-0.8)	0.7 (0.5-1.0)	0.6 (0.4-0.8)	0.6 (0.4-0.8)	<0.001
Sodium, MeQ/l	4,057	137 (134-140)	137 (134-140.5)	137 (134-140)	138 (135-141)	< 0.001
Creatinine, mg/dl	4,156	1.0 (0.8-1.6)	1.0 (0.8-1.6)	1.0 (0.8-1.5)	1.0 (0.7-1.6)	0.004
Prothrombin time, s	2,604	13.7 (12.0-15.3)	14.7 (13.6-16.6)	13.4 (8.2-14.5)	13.7 (11.5-15.7)	<0.001
Partial thromboplastin time, s	2,501	16.6 (13.8-31.3)	16.6 (14.3-31.0)	17.9 (13.7-32.0)	15.8 (13.5-30.5)	0.02
International normalized ratio	2,743	1.1 (1.0-1.3)	1.2 (1.1-1.4)	1.1 (1.0-1.2)	1.1 (1.0-1.3)	< 0.001
Platelet count, cells/mm ³	4,129	211 (161-280)	227 (167-303)	207 (160-270)	210.5 (156-276)	<0.001

Values are median (interquartile range), n (%), or n/N (%), unless otherwise indicated. Values at baseline are within 48 h of admission. *Chi-square test used for categorical variables. Kruskal-Wallis test used for continuous variables.

 $\mathsf{ACE} = \mathsf{angiotensin-converting} \ \mathsf{enzyme}, \ \mathsf{ARB} = \mathsf{angiotensin} \ \mathsf{receptor} \ \mathsf{blocker}.$

Landmark analyses were considered at 3 different time points: days 2, 3, and 4 after hospital admission (Supplemental Appendix). All analyses were conducted using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina).

RESULTS

PATIENT AND HOSPITAL PRESENTATION CHARACTERISTICS.

A total of 4,389 patients met inclusion criteria for analysis (Supplemental Figure 2). The median age was 65 years (interquartile range: 53 to 77 years), 44% were women, 26% self-identified as African American, and 27% as Hispanic/Latino. Table 1 shows baseline characteristics and laboratory values stratified by therapeutic AC (n = 900), prophylactic AC (n = 1,959), and no AC (n = 1,530). Pre-hospital medications of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, prior AC, and antiplatelet therapy by group are also shown in Table 1. Approximately one-tenth of the total cohort were on AC or antiplatelet medications prior to admission (1.8% and 8.5%, respectively). On hospital presentation, patients in the therapeutic AC group had higher blood pressures, faster heart and respiratory rates, and lower oxygen saturation (Table 1). D-dimer concentrations were highest in the patients who received therapeutic AC (median 2.3 µg/ml; interquartile range: 1.2 to 5.8 µg/ml). Elevated inflammatory markers including ferritin, lactate dehydrogenase, and c-reactive protein increased progressively from the no AC to prophylactic AC and then therapeutic AC patient groups.


MORTALITY, INTUBATION, AND OUTCOMES. Overall, 1,073 (24.4%) patients died during the study period, 2,892 (65.9%) were discharged alive, and 424 (9.7%) were still hospitalized by dataset freeze date. Among the no AC group, 931 (60.8%) patients were discharged alive, 392 (25.6%) expired in the hospital, and 207 (13.5%) were still hospitalized. In the prophylactic AC group, 1,472 (75.1%) patients were discharged alive, 424 (21.6%) expired in the hospital, and 63 (3.2%) were still hospitalized. Finally, in the therapeutic AC group, 89 (54.3%) patients were discharged alive, 257 (28.6%) expired in the hospital, and 154 (17.1%) were still hospitalized. Therapeutic AC was associated with a 47% reduction in the hazard of in-hospital mortality (aHR: 0.53; 95% CI: 0.45 to 0.62; p < 0.001) (Figure 1A) compared with no AC. Similarly, prophylactic AC was associated with a lower hazard of mortality (aHR: 0.50; 95% CI: 0.45 to 0.57; p < 0.001) compared with no AC. Overall, 467 (10.6%) patients required intubation and mechanical ventilation during hospitalization. Therapeutic AC was associated

with a 31% reduction in the hazard of intubation (aHR: 0.69; 95% CI: 0.51 to 0.94; p = 0.02) (Figure 1B) compared with no AC. Prophylactic AC was also associated with similarly reduced incidence of intubation (adjusted HR: 0.72; 95% CI: 0.58 to 0.89; p = 0.003) compared with no AC. Landmark analyses showed similar associations (Supplemental Tables 2 and 3).


THERAPEUTIC AND PROPHYLACTIC DOSE AC. We conducted a subanalysis for patients initiated on therapeutic (n = 766) or prophylactic doses (n = 1,860) of AC \leq 48 h of admission. Baseline characteristics are presented in Supplemental Table 4. Patients who received therapeutic AC were older, had more comorbid conditions, and were more likely to be on an anticoagulant prior to admission compared with those receiving prophylactic AC. Patients on therapeutic AC also presented with more altered vital signs and inflammatory markers, in particular D-dimer (2.4 µg/ml vs. 1.4 µg/ml) compared with those receiving prophylactic AC. In adjusted analyses, therapeutic AC was associated with lower in-hospital mortality (aHR: 0.86; 95% CI: 0.73 to 1.02; p = 0.08) (Figure 2A), although not statistically significant. There was no difference in incidence of intubation (aHR: 0.94; 95% CI: 0.74 to 1.21; p = 0.63) (Figure 2B).

BLEEDING OUTCOMES. A total of 153 patients met the pre-specified definition of major bleeding. Of these, 89 either had a confirmed or suspected bleed (Supplemental Figure 3). For patients on AC, bleeding was counted only if it occurred after initiation of treatment. The proportion of patients with bleeding events after initiation of AC treatment was highest in patients on therapeutic AC (27 of 900; 3.0%) compared with patients on prophylactic AC (33 of 1,959; 1.7%) and no AC (29 of 1,530; 1.9%) (Supplemental Table 5). Among patients on a single therapeutic agent, bleeding rates were higher in those on low molecular weight heparin (LMWH) compared with direct oral anticoagulants (DOACs) (2.6% vs. 1.3%, respectively), and among those on a single prophylactic agent, bleeding rates were higher in those on unfractionated heparin (UFH) compared with LMWH (1.7% vs. 0.7%, respectively). The site of bleeding was determined in 67 of 89 (75%), with gastrointestinal being most common (50.7%), followed by mucocutaneous (19.4%), bronchopulmonary (14.9%), and then intracranial (6%).

ANTICOAGULATION AGENTS. A sizable proportion of patients were on more than 1 AC agent over the course of their hospitalization, preventing direct comparisons between anticoagulants. In a descriptive



analysis, we present differences in cumulative incidence of mortality and intubation among individuals who were on a single anticoagulant received within 48 h of admission. Among patients on therapeutic AC, differences in mortality and intubation between DOACs (n = 178) versus LMWH (n = 211) are shown in Supplemental Figures 4A and 4B, respectively, and suggest that DOACs may



be associated with better survival and lower intubation rates compared with LMWH. Patients on UFH were not included due to the relatively small sample size of this group (n = 35). Similarly, among

patients on prophylactic dose AC, cumulative incidence of mortality and intubation for patients on UFH (n = 941) and LMWH (n = 445) are shown in Supplemental Figures 4C and 4D, respectively.

Age Range, yr	s Sex	Prior Indication	Type of Anticoagulation	Time From Admission to Death, days		Type (Therapeutic/ Prophylactic/None)	Bleeding	Pulmonary Embolism	Microthrombi*	Suspicion of Thrombosis Before Autopsy
50-59	М	NA	UFH	9	Whole admission	Prophylactic		×	×	No
80-89	F	NA	UFH	11	Whole admission	Prophylactic			×	No
60-69	М	Atrial fibrillation	DOACs	4	Whole admission	Therapeutic			×	No
<50	М	NA	LMWH	6	Whole admission	Prophylactic		×	×	No
60-69	F	NA	None	0	NA	None				No
30-39	М	NA	LMWH	7	Whole admission	Prophylactic				No
80-89	F	NA	UFH	10	Whole admission	Prophylactic			×	No
70-79	М	NA	LMWH	10	Whole admission	Prophylactic				No
<50	М	NA	None	0	NA	None				No
80-89	М	NA	None	0	NA	None				No
70-79	М	Atrial fibrillation	Warfarin	1	Whole admission	Therapeutic	Retro- peritoneal			No
<50	F	NA	UFH	3	Whole admission	Prophylactic				No
80-89	F	NA	UFH	1	Whole admission	Prophylactic				No
70-79	М	Deep venous thrombosis	DOACs	1	Whole admission	Prophylactic			×	No
50-59	М	NA	UFH	4	1 day	Subtherapeutic [†]		×		No
50-59	М	NA	UFH, LMWH	5	Whole admission	Prophylactic				No
60-69	М	NA	None	1	-	None		×		No
50-59	М	NA	UFH, LMWH	5	Whole admission	Prophylactic				No
70-79	F	NA	LMWH	6	Whole admission	Prophylactic				No
50-59	F	NA	UFH	4	Whole admission	Prophylactic			×	No
70-79	F	Atrial fibrillation	DOACs	5	Whole admission	Therapeutic				No
50-59	F	NA	UFH, LMWH	15	2 days	Therapeutic				No
80-89	F	NA	LMWH	10	Whole admission	Prophylactic				No
70-79	М	NA	UFH	9	Whole admission	Therapeutic				No
60-69	М	NA	UFH	22	5 days	Therapeutic			×	No
<50	М	NA	UFH	11	1 day	Subtherapeutic†			×	Yes


*Organs assessed for microthrombi in hematoxylin and eosin include heart (found in 4 of 26), kidneys (found in 2 of 26), liver (found in 1 of 26), lymph nodes (found in 2 of 26) and brain (found in 2 of 26). Microthrombi in the lungs are normally seen as part of diffuse alveolar damage and are discussed separately (see Results and Discussion sections). †Anticoagulation in this case was intended to be therapeutic; however, PTT never reached the therapeutic range.

DOAC = direct oral anticoagulant; LMWH = low molecular weight heparin; NA = not applicable; UFH= unfractionated heparin.

Patients on prophylactic DOACs are not shown due to limited sample size (n = 34).


AUTOPSY FINDINGS. Autopsies were performed on COVID-19 positive patients at Mount Sinai Health System starting on March 20, 2020, with 72 completed by May 7, 2020 (8). Of these, the first 26 sequential cases were evaluated microscopically by a team of subspecialty pathologists across organ systems. These cases are presented with a focus on thromboembolism and contextualized by premortem AC regimens (Table 2). Among 26 patients, 4 were on AC prior to admission due to atrial fibrillation (n = 3) or prior DVT (n = 1) (3 on DOACs, 1 on warfarin). Of the remaining 22 patients, 4 died within 24 h of presentation without ever receiving AC, 14 were placed on AC upon admission (13 prophylactic, 1 therapeutic), and 4 received AC later during their hospital course (mean number of days post-admission: 2.3).

In total, 11 of 26 (42%) had evidence of thromboembolic disease, including 4 patients with pulmonary emboli (15%) (Figures 3A and 3B); 2 patients with cerebral infarctions (8%) (Figures 3C and 3D); and 5 patients with microthrombi in multiple organs including the heart (n = 4) (Figure 3E), liver (n = 1)(Figure 3F), kidneys (n = 2, not shown), and lymph nodes (n = 2, not shown). The lungs were examined and revealed an extensive burden of fibrin thrombi visible on hematoxylin and eosin stain (15 of 26); however, this was not counted toward the thrombotic burden as it is an expected and frequently encountered finding in diffuse alveolar damage. Of the 4 patients with pulmonary emboli, 2 were on prophylactic AC throughout, 1 was not on AC, and 1 was given AC using UFH to treat disseminated intravascular coagulation but at subtherapeutic levels. More generally, 8 of 11 (73%) patients with thromboemboli were not on therapeutic AC. There was no premortem suspicion of thromboemboli in 25 of 26 patients. There was only 1 major bleeding complication, which was a retroperitoneal bleed on presentation in a patient taking warfarin for atrial fibrillation prior to admission.



DISCUSSION

Thromboembolic disease has emerged as an important complication among hospitalized patients with COVID-19. In the present report of nearly 4,400 patients, we demonstrate the following findings (Central **Illustration**). First, AC is associated with lower hazards of in-hospital mortality and intubation compared with no AC after controlling for relevant clinical factors. Second, after restricting analysis to those in whom AC was initiated within 48 h of admission, no statistically significant difference in in-hospital



mortality or intubation for therapeutic versus prophylactic AC was observed. Third, overall rates of major bleeding were low. Finally, these observations were corroborated by autopsy findings, wherein 11 of 26 of patients had thromboembolic disease not otherwise suspected premortem. The majority of these patients were not treated with therapeutic AC.

The mechanisms by which thrombotic disease may occur in the setting of COVID-19 infection include inflammation, hypoxia, and potentially pharmacotherapeutic interactions (2,4,12,13). As such, the potential benefit of AC in the treatment of COVID-19 is based on the prevention and treatment of microvascular and macrovascular thrombosis. In addition, AC agents may exert antiviral and anti-inflammatory properties affording further benefit (14,15).

In our cohort of patients hospitalized with COVID-19, a strong association of AC with approximately 50% reduced hazard of in-hospital mortality was observed (**Figure 1A**). Both therapeutic and prophylactic doses of AC were associated with better in-hospital survival compared with no AC. As mortality

rates for patients with COVID-19 who undergo intubation for respiratory failure range from 30% to 80% (16–18), we analyzed the association between AC and intubation. Both therapeutic and prophylactic AC were associated with an approximately 30% reduced hazard of intubation compared with patients on no AC (Figure 1B). Landmark analyses were performed to minimize immortal time bias and revealed similar associations (Supplemental Tables 2 and 3).

THERAPEUTIC COMPARED WITH PROPHYLACTIC DOSE AC. Due to variation in timing of initiation and administration of AC across patients, a subanalysis of patients who received either therapeutic or prophylactic AC within 48 h of admission showed that therapeutic AC was associated with a 14% reduction in hazard of mortality compared with prophylactic AC that did not reach statistical significance (p = 0.08). There was no difference in intubation risk between the 2 doses (**Figures 2A and 2B**).

In entirely descriptive analyses examining individual agents, potential benefit with prophylactic LMWH compared with UFH may exist for mortality, but differences in intubation appear minimal. Therapeutic DOACs visually may be associated with lower mortality and intubation risk compared with LMWH (Supplemental Figure 4). No conclusions can be drawn from these purely descriptive comparisons, however, and randomized trials comparing specific agents are needed to inform whether comparative benefit exists.

BLEEDING. Bleeding rates were low overall, but as expected, were slightly higher in the therapeutic AC group compared with the prophylactic and no AC groups (Table 2). In patients on a single therapeutic agent, the bleeding rates were higher in patients on LMWH versus DOACs. Further studies and trials are required, however, to better understand this observation. As always, the benefit-risk tradeoff, here between AC and bleeding, needs to be evaluated on an individual basis and discussed as part of shared-decision making.

AUTOPSY FINDINGS. We show a high prevalence of thrombotic complications mostly occurring in patients receiving prophylactic/no AC, consistent with a recent autopsy study demonstrating thrombotic burden in 58% (6,19). Although lung microthrombi were not counted toward overall burden but rather as a feature of diffuse alveolar damage, it is worth noting that this finding emphasizes the endothelial dysfunction at play. Finally, in all except for 1 case of stroke, there was no clinical suspicion of thromboembolic disease prior to autopsy, suggesting that clinical estimates of thromboembolic disease may be underestimating the actual burden.

STUDY LIMITATIONS. As an observational study, there may have been confounders leading to differences in the outcomes for the treatment groups. Although we minimized their potential impact through IPTW modeling, unmeasured confounders and residual bias may have been present. Despite a 2-physician manual review of different AC regimens for the purposes of categorizing patients, there may have been discrepancies between regimens of DOACs and LMWH wherein doses may not have accurately represented therapeutic and prophylactic AC. Patients who were on both therapeutic and prophylactic doses of AC were excluded due to an inability to definitively categorize them. Patients with hospital stay <24 h were also excluded. Nonetheless, we adopted a conservative approach wherein individuals receiving <48 h of AC were considered in the "no AC" group. To minimize immortal time bias, we analyzed AC as a time-dependent variable and conducted landmark sensitivity analyses. However, we cannot rule out residual bias even after using IPTW. We included UFH infusion in the therapeutic group, but patients may not be in the therapeutic activated partial thromboplastin time range. Because manual validation of each outcome was not feasible in the whole sample size, there exists the possibility of misclassification of outcomes. We did not conduct analysis on novel antiviral treatments (remdesivir, interleukin-1 antagonists) because these were still under investigation and administered in the context of clinical trials at our institution. The generalizability of the autopsy data may be limited due to small sample size and the fact that these were not consecutive deaths. Finally, we may have encountered higher proportions of patients on AC due to the fact that Mount Sinai initiated a system-wide protocol, wherein at least prophylactic AC was strongly encouraged with guidance provided for consideration of therapeutic AC based on various factors (Supplemental Figure 5).

CONCLUSIONS

Among patients hospitalized with COVID-19, AC was associated with a lower adjusted risk of mortality and intubation versus no AC. Rates of major bleeding were low. Consecutive autopsies revealed frequent thromboembolism, with most patients not on therapeutic AC. The results of randomized controlled trials evaluating different AC regimens for treatment for hospitalized patients with COVID-19 are needed.

ACKNOWLEDGMENTS The authors thank all of the nurses, physicians, and providers who contributed to the care of these patients, as well as the patients and their family members who were affected by this pandemic.

ADDRESS FOR CORRESPONDENCE: Dr. Valentin Fuster, The Icahn School of Medicine at Mount Sinai, The Mount Sinai Hospital, One Gustave L Levy Place, New York, New York 10029. E-mail: valentin.fuster@ mountsinai.org. OR Dr. Anuradha Lala, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute, One Gustave L. Levy Place, Box 1030, New York, New York 10029. E-mail: anu.lala@mountsinai.org. Twitter: @girish_nadkarni, @dranulala, @emiliabagiella.

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: In an observational study of patients hospitalized with COVID-19, intubation and mortality were less frequent among those managed with anticoagulation at prophylactic or therapeutic doses than those not anticoagulated. Bleeding rates were generally low. Consecutive autopsy samples revealed a high incidence of thromboembolism.

TRANSLATIONAL OUTLOOK: Clinical trials are needed to identify predictors of thromboembolism and bleeding and establish optimum antithrombotic strategies for patients with COVID-19 at various stages of illness and hospitalization.

REFERENCES

1. Johns Hopkins University of Medicine. Global map: COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at: https:// coronavirus.jhu.edu/map.html. Accessed June 12, 2020.

2. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-ofthe-art review. J Am Coll Cardiol 2020;75: 2950-73.

3. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol 2020;189:846-7.

4. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020;7: e438-40.

5. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135:2033-40.

6. Wichmann D, Sperhake J-P, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 2020;173:268-77.

7. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Heide RSV. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 2020;8:681-6.

8. Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. medRxiv 2020 May 21 [E-pub ahead of print].

9. Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 2020;76:122-4.

10. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094–9.

11. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.

12. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023-6.

13. Pilli VS, Datta A, Afreen S, Catalano D, Szabo G, Majumder R. Hypoxia downregulates protein S expression. Blood 2018;132:452-5.

14. de Haan CAM, Li Z, te Lintelo E, Bosch BJ, Haijema BJ, Rottier PJM. Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor. J Virol 2005;79:14451-6. **15.** Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A 2009;106: 5871-6.

16. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region-case series. N Engl J Med 2020;382: 2012-22.

17. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA 2020;323:2195-8.

18. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323:2052-9.

19. Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med 2020 May 14 [E-pub ahead of print].

KEY WORDS anticoagulation, COVID-19, intubation, mortality

APPENDIX For an expanded Methods section as well as supplemental tables and figures, please see the online version of this paper.